The clock is ticking: Final 24 hours to exhibit at TechCrunch Disrupt 2026
THE SO WHAT
If you’re still deciding whether to exhibit at a mass event like Disrupt, treat it as a brand and learning spend, not a direct pipeline bet. The real ROI is often in concentrated side meetings and signal-gathering, not foot traffic to a table.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureUK Sovereign AI Fund in talks to back £500m raise for drug discovery startup
If the UK’s sovereign AI vehicle is anchoring a £500m raise into drug discovery, national AI strategy is moving from chips and models into domain-specific IP. Biotech operators should expect more state-backed AI competitors and tighter competition for top applied ML talent.
Startups & VentureImmunology Drugmaker Electra Opens Flat After Upsized US IPO
Electra Therapeutics raising $350m in an upsized IPO but trading flat suggests public markets will fund late-stage biotech, but without the 2021-style pop. Biotech operators should plan for capital access with muted aftermarket enthusiasm—story and pipeline depth matter more than listing optics.
Startups & VentureFamily offices are clamoring for AI investments
Family offices piling into AI is fresh capital but also a classic late-cycle signal—check whether your round is being priced on fundamentals or fear of missing the next OpenAI. Founders should use this window to strengthen balance sheets, not to overextend burn on speculative bets.
Startups & VentureRevolut plans a dual London and Nasdaq listing, Storonsky tells Les Echos
Revolut targeting a dual London–Nasdaq listing is a bid to capture US liquidity without abandoning UK roots—fintechs are optimizing for both regulatory familiarity and valuation. Late-stage European startups should revisit where their eventual listing narrative actually resonates with investors and customers.